angiotensin ii, des-asp(1)-des-arg(2)-ile(5)- and alpha-synuclein

angiotensin ii, des-asp(1)-des-arg(2)-ile(5)- has been researched along with alpha-synuclein in 1 studies

Compound Research Comparison

Studies (angiotensin ii, des-asp(1)-des-arg(2)-ile(5)-)	Trials (angiotensin ii, des-asp(1)-des-arg(2)-ile(5)-)	Recent Studies (post-2010) (angiotensin ii, des-asp(1)-des-arg(2)-ile(5)-)	Studies (alpha-synuclein)	Trials (alpha-synuclein)	Recent Studies (post-2010) (alpha-synuclein)
311	5	64	10,821	29	8,011

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Grammatopoulos, TN; Hyman, BT; Outeiro, TF; Standaert, DG	1

Other Studies

1 other study(ies) available for angiotensin ii, des-asp(1)-des-arg(2)-ile(5)- and alpha-synuclein

Article	Year
Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro. Biochemical and biophysical research communications, 2007, Nov-23, Volume: 363, Issue:3 Topics: alpha-Synuclein; Angiotensin II; Cell Line, Tumor; Electrophoresis, Polyacrylamide Gel; Humans; Imidazoles; Immunoblotting; Inclusion Bodies; Losartan; Parkinson Disease; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Vasoconstrictor Agents	2007

Article

Year

Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro.

Biochemical and biophysical research communications, 2007, Nov-23, Volume: 363, Issue:3

Topics: alpha-Synuclein; Angiotensin II; Cell Line, Tumor; Electrophoresis, Polyacrylamide Gel; Humans; Imidazoles; Immunoblotting; Inclusion Bodies; Losartan; Parkinson Disease; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Vasoconstrictor Agents

2007